# What the October 2026 compounding notice covers

- Article ID: research-043
- Product: BPC-157 (bpc-157-632, bpc-157-430)
- Canonical page: https://heritagebiolabs.com/research-library/articles/043-what-the-october-2026-compounding-notice-covers
- Product collection: https://heritagebiolabs.com/research-library/products/bpc-157
- Product page: https://heritagebiolabs.com/product/bpc-157-632
- Product page: https://heritagebiolabs.com/product/bpc-157-430
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Amino acids linked by peptide bonds form short chains called peptides. Some change how cells respond to signals, while others are studied to learn whether they have such activity. BPC-157 is a synthetic 15-amino-acid peptide investigated in tissue injury models. In October 2026, the U.S. Department of Health and Human Services published a notice about an interim policy on certain peptide bulk drug substances. The notice and its accompanying policy address a regulatory question about compounding. [1] [2]

The policy describes circumstances in which HHS does not intend to take enforcement action while a list of bulk drug substances is developed through rulemaking under section 503A of federal law. Its appendix identifies BPC-157 acetate and describes the conditions that apply. These include requirements for the identity and quality of the bulk substance, adverse event reporting and a single active ingredient in the compounded product. The policy applies to specified compounders under the stated conditions. [1] [2]

Drug approval asks a separate question. It involves evidence that a particular finished product is safe and effective for a defined use, along with manufacturing and labeling review. The HHS notice describes enforcement discretion, so a product covered by its conditions does not acquire an FDA-approved indication through that policy. A laboratory study of a peptide also cannot answer the same question as a controlled clinical trial of a defined product. [1] [2]

That distinction helps explain why two statements can be true at once. An agency can describe limited conditions for compounding while researchers still need clinical evidence on outcomes. A specification for a bulk ingredient establishes what substance the policy addresses. Clinical evidence is what would determine whether an intervention improves a specific health outcome. [1] [2]

## Sources

1. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register (publication 2026-10-30). <https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf>
2. U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. U.S. Department of Health and Human Services (publication 2026-10). <https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 009 - ARA-290 and BPC-157.docx; article 43; content SHA-256 cac8cef2463847df82f51dccfad9f869dd9ee152b72ac5b84c60089cee70bbeb.
